Related Experiment Video

Updated: Jan 26, 2026

Using a Pan-Viral Microarray Assay Virochip to Screen Clinical Samples for Viral Pathogens
13:45

Using a Pan-Viral Microarray Assay Virochip to Screen Clinical Samples for Viral Pathogens

Published on: April 27, 2011

19.4K

[Viral Hepatitis: When to be Considered in Clinical Routine?]

Hendrik Luxenburger, Robert Thimme, Christoph Neumann-Haefelin

    Deutsche Medizinische Wochenschrift (1946)
    |April 16, 2019
    PubMed

    Insights

    Screening for chronic viral hepatitis (Hepatitis B virus and Hepatitis C virus) is crucial for early detection and treatment, especially in high-risk populations, to prevent liver cirrhosis and cancer.

    Area of Science:

    • Hepatology
    • Infectious Diseases
    • Oncology

    Background:

    • Chronic viral hepatitis often goes undetected, posing risks for severe liver conditions like cirrhosis and hepatocellular carcinoma.
    • Early identification and management of viral hepatitis are essential for patient outcomes.

    Purpose of the Study:

    • To emphasize the importance of screening and treating viral hepatitis in at-risk individuals.
    • To highlight the role of antiviral therapy in managing HBV/HCV-associated conditions and preventing HBV reactivation.

    Main Methods:

    • The abstract does not detail specific methods but discusses screening criteria and treatment implications.
    • Focuses on identifying high-risk groups for hepatitis B virus (HBV) and hepatitis C virus (HCV) screening.

    Main Results:

    • Antiviral therapy can induce remission in HBV/HCV-associated diseases like vasculitis and lymphoma.
    • Ruling out or managing HBV infection is critical before immunosuppressive therapy to prevent reactivation.

    Conclusions:

    • Screening for chronic viral hepatitis is vital, particularly for migrants from endemic areas, individuals with a history of drug use, and men who have sex with men.
    • Prophylactic antiviral treatment is necessary to prevent fatal HBV reactivation in patients undergoing immunosuppression.

    More Related Videos

    An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use10:33

    An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

    Published on: May 24, 2024

    1.5K
    Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection11:14

    Detection of Low Copy Number Integrated Viral DNA Formed by In Vitro Hepatitis B Infection

    Published on: November 7, 2018

    18.8K

    Related Concept Videos

    Viral Recombination00:57

    Viral Recombination

    Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
    25.0K
    Viral Structure00:56

    Viral Structure

    Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
    74.1K
    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

    Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

    Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
    267
    Hepatic Portal System01:21

    Hepatic Portal System

    The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
    At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
    5.7K
    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

    Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

    Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
    222
    Viral Mutations00:36

    Viral Mutations

    A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
    39.8K